Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Intangible Assets

Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Intangible Assets · Q2 FY2026 · quarter ended Jun 2026

Intangible assets remains negative

Q2 FY2026 intangible assets was $0, compared with $0 a year earlier.

Context

  • Intangible assets amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Intangible assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Intangible Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Intangible Assets history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Intangible Assets vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's Jun 2026 intangible assets of $0 is the highest of the 5 companies compared; the peer median is $0.
  • Intangible assets amounts to 0.0% of total assets for ATNM, versus a peer median of 0.0%.
ATNM Competitors Peer median
Intangible Assets for ATNM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ATNMActinium Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
OKUROnKure Therapeutics, Inc.Mar 2026$0 ——0.0%
XLOXilio Therapeutics, Inc.Mar 2026$0 ——0.0%
PDSBPDS Biotechnology CorporationMar 2026$0 ——0.0%
ANVSAnnovis Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ATNM) $0——0.0%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents77.83M108.91M76.68M72.9M48M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets442K396K226K357K1.38M
Total Current Assets79.75M110.94M78.26M74.51M49.38M
Property, Plant & Equipment (Net)639K2.95M2.87M2.07M2.06M
Goodwill00000
Intangible Assets00000
Long-term Investments00313K324K0
Tax Assets00000
Other Non-current Assets0302K00335K
Total Non-current Assets639K3.25M3.18M2.39M2.39M
Total Assets80.39M114.19M81.45M76.9M51.78M
Account Payables5.54M10.13M7.95M7.57M0
Short-term Debt00541K0722K
Tax Payables00000
Deferred Revenue000035M
Other Current Liabilities998K000(27.75M)
Total Current Liabilities6.84M10.63M8.49M8.15M7.97M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0035M35M35M
Other Non-current Liabilities035M000
Total Non-current Liabilities3K37.08M36.57M35.99M35.97M
Total Liabilities6.84M47.71M45.07M44.14M43.94M
Common Stock22K26K28K31K31K
Retained Earnings(255.75M)(288.77M)(337.58M)(375.83M)(409.71M)
Accumulated OCI(0)(0)00(20K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity73.55M66.48M36.38M32.76M7.83M
Total Debt310K2.58M2.11M1.57M1.69M
Net Debt(77.52M)(106.33M)(74.56M)(71.33M)(46.3M)

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.